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To determine whether molecular parameters could be partly responsible for resistance or sensitivity to oxaliplatin (OX)-based
chemotherapy used as first-line treatment in advanced colorectal cancer (CRC). We studied the usefulness of the excision repair
cross-complementing 1 (ERCC1), xeroderma pigmentosum group D (XPD), XRCC1 and GSTP1 polymorphisms as predictors of
clinical outcome in these patients. We treated 126 CRC patients with a first-line OX/5-fluorouracil chemotherapeutic regimen.
Genetic polymorphisms were determined by real-time PCR on an ABI PRISM 7000, using DNA from peripheral blood. Clinical
response (CR), progression-free survival (PFS) and overall survival (OS) were evaluated according to each genotype. In the univariate
analysis for CR, ERCC1-118 and XPD 751 polymorphisms were significant (P¼ 0.02 and P¼ 0.05, respectively). After adjustment for
the most relevant clinical variables, only ERCC1-118 retained significance (P¼ 0.008). In the univariate analysis for PFS, ERCC1-118
and XPD 751 were significant (P¼ 0.003 and P¼ 0.009, respectively). In the multivariant analysis, only the XPD 751 was significant for
PFS (P¼ 0.02). Finally, ERCC1-118 and XPD 751 polymorphisms were significant in the univariate analysis for OS (P¼ 0.006 and
P¼ 0.015, respectively). Both genetic variables remained significant in the multivariate Cox survival analysis (P¼ 0.022 and P¼ 0.03).
Our data support the hypothesis that enhanced DNA repair diminishes the benefit of platinum-based treatments.
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The introduction of oxaliplatin (OX) into treatment regimens for
advanced colorectal cancer (CRC) represented a significant
advance in the success of chemotherapy. The synergistic effects
of 5-fluorouracil (5-FU) and OX have increased response rates
by up to 50% in first-line-treated patients (Saunders and Iveson,
2006), allowing surgery of isolated liver metastases that were
previously considered unresectable. Oxaliplatin, a platinum-based
chemotherapeutic agent that carries a 1,2-diamino-cyclohexane
ring, has shown antitumour efficacy in vitro and in vivo. This
bulky carrier group is considered to promote the formation of
platinum– DNA adducts. As these adducts are more cytotoxic than
those formed from other platinum agents, they are more effective
in blocking DNA replication (Raymond et al, 1998). These adducts
are recognised and repaired by the nucleotide excision repair
(NER) pathway, which is a major cellular defence mechanism
against the cytotoxic effects of platinum-based chemotherapeutic
agents (Reed, 2005). The repairosome responsible for excision
involves a number of genes, including excision repair cross-
complementing 1 (ERCC1). This protein forms a heterodimer with
xeroderma pigmentosum group F to execute the incision into the
DNA strand, 50 to the site of damage. There is also a co-ordinate
expression of the xeroderma pigmentosum group D (XPD) with
ERCC1 and other genes in the NER repairosome complex.
The ERCC1 gene, on chromosome 19q13.2–q13.3, encodes a
protein of 297 amino acids. A number of polymorphisms have been
identified in this gene: (i) a common single-nucleotide polymor-
phism (SNP) at codon 118, position 19007, that causes a C4T
change coding for the same amino acid, asparagine; (ii) a second
common SNP, located in position 8092 of the 30-untranslated region,
consisting of a C4A change; and (iii) an SNP (G4C) located in
intron 3, position 19716. The XPD gene (also called ERCC2) maps on
chromosome 19q13.3 and covers 21.14 kb of genomic DNA.
Although several polymorphisms have been reported in this gene,
the most frequent is the A751C polymorphism, which causes the
substitution of a lysine residue by a glutamine.
Another repair mechanism, known as the base excision repair
system (BER), has been identified in human cells. In this system,
the XRCC1 protein interacts with DNA ligase III and complexes
with DNA polymerase and PARP (polyADP-ribose polymerase),
facilitating the repair of DNA strand breaks and several types of
DNA damage (Dianov, 2003). The XRCC1 gene contains 17 exons
and is located on chromosome 19q13.2. Although many poly-
morphisms have been documented, three non-synonymous
polymorphisms, Arg194Trp (C4T), Arg280His (G4A) and
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Arg399Gln (G4A), have been shown to impair DNA-repair
capacity in some phenotypic studies.
Glutathione S-transferases (GST) are a multigene family of
enzymes (cytosolic and membrane bound that catalyse the
conjugation of glutathione to electrophilic xenobiotics to inactivate
them and facilitate their excretion from the body). Glutathione
S-transferases have an important function in the metabolism of
potentially genotoxic compounds by preventing DNA damage and
adduct formation. GSTP1, an isoenzyme belonging to the p class,
participates in the detoxification of platinum derivatives and is an
important mediator of both intrinsic and acquired resistance to
platinum (Cullen et al, 2003). The gene coding for GSTP1 is located
on chromosome 11q13. The most studied polymorphism is an A4G
substitution in position 313 in exon 5 that gives rise to Ile105Val.
In this work, we sought to determine whether different mole-
cular parameters could be responsible in part for resistance or
sensitivity to OX-based chemotherapy used as first-line treatment
in advanced CRC patients. We studied the usefulness of the
ERCC1, XPD, XRCC1 and GSTP1 polymorphisms as predictors of
the clinical outcome of these patients.
MATERIALS AND METHODS
Patients
One hundred and twenty-six patients diagnosed with metastatic
CRC and receiving OX combined with 5-FU as first-line
chemotherapy were included in the study. All patients had
adequate bone marrow and organ function before treatment.
Written informed consent was obtained, and the study was
approved by the Institutional Ethics Committee.
Chemotherapy regimen description
We administered a uniform chemotherapy regimen in this group
of patients. It consisted of OX (85 mg m2 infused for 2 h every
2 weeks i.v.) and 5-FU (a pulse dose of 400 mg m2 on days 1 and
2 and a continuous infusion of 1200 mg m2 for 44 h) with i.v.
leucovorin. Patients underwent chemotherapy cycles until severe
toxicity or disease progression appeared.
Clinical parameters
Relevant clinical data (gender, age, ECOG, adjuvant therapy,
number of chemotherapy cycles, number of metastatic sites, colon
vs rectum involvement, WBC count, alkaline phosphatase) were
obtained from clinical records. We used four baseline clinical
parameters (performance status, WBC count, alkaline phosphatase
and number of metastatic sites) to classify the patients into three
clearly separated risk groups (Kohne et al, 2002). The model was
adjusted to take this clinical risk classification into account in the
multivariate analysis.
We also considered patients with isolated hepatic metastases
because chemotherapy in these cases produced a sufficient
reduction in tumour size to make curative resection feasible.
Response to treatment and progression-free survival (PFS) and
overall survival (OS) were also analysed. Clinical response (CR),
which was defined in accordance with WHO criteria (WHO, 1979),
was assessed by CT scan every 3 months after the start of
chemotherapy. Progression-free survival was defined as the time
from the start of chemotherapy to the first occurrence of disease
progression or death. Overall survival was calculated from the start
of chemotherapy to death regardless of the cause.
Cumulative OX-induced neuropathy was scored on the
OX-specific scale reported earlier (Caussanel et al, 1990).
According to this scale, the grade of cumulative neuropathy
depends on the duration and intensity of symptoms (grade 1:
paraesthesia, dysesthesia of short duration; grade 2: paraesthesia,
dysesthesia persisting between cycles; grade 3: paraesthesia,
dysesthesia causing functional impairment).
Genetic analysis
Genomic DNA was extracted from peripheral leukocytes by the
salting-out procedure (Miller et al, 1988). All polymorphisms were
analysed by means of real-time PCR on an ABI PRISM 7000
Sequence Detection System (Applied Biosystems, Foster City, CA,
USA). The TaqMan probes employed are given in Table 1. Each
reaction contained template DNA and a final concentration of
1 TaqMan PCR Master Mix (Applied Biosystems), 300 nM of
each primer, 100 nM of wild-type probe (Applied Biosystems)
and 100 nM of variant probe (Applied Biosystems). Thermocycling
was performed with an initial 501C incubation for 2 min followed
by a 10-min incubation at 951C. A two-step cycling reaction was
performed for 40 cycles, with denaturation at 921C for 15 s and
annealing/extension at 601C for 1 min. Analysis of the amplifica-
tion reaction was undertaken using the Sequence Detector
software, version 2.0 (Applied Biosystems). Data were analysed
using Allelic Discrimination Program (Applied Biosystems).
For each polymorphism, a minimum of 10 randomly selected
DNA samples were sequenced to confirm the results and were
subsequently used as controls.
Statistical analysis
Differences between categorical variables were measured by the
w2 test. Logistic regression was used as a multivariate method
to ascertain which variables independently predicted CR. Kaplan–
Meier estimates and the log-rank tests were employed in the
univariate analysis of PFS and OS. A Cox regression model was
used for PFS and OS multivariate analyses. The results were
considered statistically significant when bilateral P-values were less
than 0.05. We estimated classical LD measures D0 and r2 with the
software LDA (Ding et al, 2003).
RESULTS
The frequencies of the different alleles of the genetic markers
analysed (Table 1) showed values (data not shown) similar to those
reported in Caucasian populations.
Table 1 Genetic markers evaluated in this study
Polymorphism dbSNP NCBI Ref Seq Exon Genotype Amino-acid substitution/position
ERCC1 Asn118Asn rs11615 NM_001983 4 C/T Asn/118
ERCC1 G19716C rs3212948 NM_001983 Intron 3 G/C —
ERCC1 C8092A rs3212986 NM_001983 30-UTR C/A —
XPD Lys751Gln rs13181 NM_000400 23 A/C Gln/751
GSTP1 Ile105Val rs1695 NM_000852 5 A/G Val/105
XRCC1 Arg194Trp rs1799782 NM_006297 6 C/T Trp/194
XRCC1 Arg280His rs25489 NM_006297 9 G/A His/280
XRCC1 Arg399Gln rs25487 NM_006297 10 G/A Gln/399
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Two SNPs in the ERCC1 gene, located in intron 3 and exon 4,
were in high linkage disequilibrium (D0 ¼ 1, r2¼ 0.86) (LD:
Po0.00001): alleles with a C residue in ERCC1-118 contained a
G residue in position 19716 and alleles with a T in codon 118
carried a C residue in position 19716. As both SNPs gave almost
the same information for association analysis, from here on, we
consider only the function of ERCC1-118.
Genetic determinants and response
Clinical data are given in Table 2. A total of 126 patients who
fulfilled all inclusion criteria were evaluated for response.
Two genetic markers were significantly associated with
response: C118T in the ERCC1 gene (P¼ 0.02) and A751C in the
XPD gene (P¼ 0.05). Table 3 shows the relationships between
response and these molecular determinants.
The C118T in the ERCC1 gene maintained its predictive value in
a logistic regression model of response (P¼ 0.008). The probability
of response was 3.7 times greater in patients with a TT or a C/T
genotype than in patients with a C/C genotype (CI 95%; relative
risk (RR): 1.4– 9).
Genetic determinants and survival
With regard to PFS, the two variables, the ERCC1-118 and the XPD
751 SNPs, showed a predictive value. For ERCC1-118, the median
PFS was 10 months for TT and C/T cases and 6 months for C/C
patients (P¼ 0.003) (Figure 1A). For XPD 751, the median PFS was
12 months for A/A patients and 8 months for A/C and C/C patients
(P¼ 0.009) (Figure 1B). Only XPD 751 and the clinical risk variable
remained significant in the multivariant analysis. A/C and C/C
patients had a 1.7 increased risk to progress than A/A patients
(RR 1.1–2.8, P¼ 0.02).
As for OS, the ERCC1-118 and the XPD 751 SNPs defined
significantly different survival groups of patients. For ERCC1-118,
the median OS was 30 months for T/T and C/T and 11 months for
C/C cases (P¼ 0.006) (Figure 2A). For the XPD 751, the median OS
was 41 months for AA patients and 17 months for A/C and C/C
patients (P¼ 0.015) (Figure 2B). Only ERCC1-118 and XPD 751
SNPs remained significant in the multivariate Cox survival analysis
(P¼ 0.022; RR¼ 1.8; CI 95%: 1.1– 3 and P¼ 0.03; RR¼ 1.6; CI 95%:
1.1–2.5, respectively).
Genetic determinants and neurotoxicity
We analysed whether the GSTP1 Ile105Val polymorphism was
associated with OX-related cumulative neuropathy in this group of
patients. A median of 10 cycles per patient (range 6–16) was
administered. The median dose intensity of OX was 85 mg m2 per
2 weeks and the median cumulative dose of OX was 850 mg m2
(range 510–1360). Maximal peripheral neuropathy was grade 3
in 4% (five patients), grade 2 in 52.4% (66 patients) and grade 1 in
32.5% (42 patients). No neurotoxicity was detected in the
remaining patients. The distribution of the exon 5 GSTP1 genotype
was 35% for the Ile/Ile genotype (44 patients), 49% for the Ile/Val
genotype (62 patients) and 16% for the Val/Val genotype
(20 patients). Our allele frequency for the Val allele was 0.4 (102
of 252) and resembled earlier reports on allele frequencies for
healthy Caucasians and for CRC patients (Watson et al, 1998;
Welfare et al, 1999).
Grade 2 and 3 cumulative peripheral neuropathy was more
common in patients with the Ile/Ile genotype (29/44 patients, 66%)
than in patients with Ile/Val or Val/Val genotype (42/82 patients,
51%), but the difference did not reach statistical significance
(P¼ 0.08).
Genetic determinants and resectability of liver metastases
Sixty-four of 126 patients (51%) had isolated hepatic metastases at
diagnosis. Surgery was performed after chemotherapy when there
was a sufficient reduction in tumour size (25/64; 39%). Twenty-two
of the 25 patients (88%) underwent radical liver surgery with
curative intent and three were treated with partial liver surgery.
The median OS was 33 months in the group of patients
with isolated hepatic metastases and 19 months in the remaining
cases (P¼ 0.024). The median OS was 46 months in the patients
Table 2 Baseline characteristics of the 126 patients
Gender (men/women) 81 (64%)/45 (36%)
Median age (range, years) 66 (34–83)
Performance status
0–1 101 (80%)
41 25 (20%)
Adjuvant therapy
No 89 (71%)
chemotherapy 24 (19%)
chemotherapyþ radiotherapy 13 (10%)
Number of cycles of chemotherapy
Median (range) 9 (1–20)
Number of patients with isolated hepatic metastases
Yes 64 (51%)
No 62 (49%)
Number of patients receiving surgery after QT
Yes 25 (20%)
No 39 (80%)
Primary tumour localisation
Colon 45 (36%)
Rectum–sigma 81 (64%)
Alkaline phosphatase levels
o300 U l1 105 (83%)
X300 U l1 21 (17%)
WBC count
o10 109 per l 113 (90%)
X10 109 per l 13 (10%)
Risk classification
High risk 21 (17%)
Intermediate risk 38 (30%)
Low risk 67 (53%)
Table 3 Positive relationships between response and molecular
determinants
No clinical response Clinical response P
ERCC1-118 0.02
TT 16 (38%) 26 (62%)
CT 21 (40%) 31 (60%)
CC 17 (71%) 7 (29%)
ERCC1-19716 0.04
G/G 14 (70%) 6 (30%)
C/G 23 (40%) 35 (60%)
C/C 18 (38%) 29 (62%)
XPD 751 0.05
AA 17 (33%) 35 (67%)
AC 23 (51%) 22 (50%)
CC 14 (58%) 10 (42%)
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who underwent surgery and 19 months in the remaining
cases (P¼ 0.001). There was no association between the genetic
markers analysed and the probability of receiving surgery after
chemotherapy.
DISCUSSION
Pharmacogenetic data concerning CRC patients treated with
platinum-based chemotherapeutic regimens are scarce and some-
times contradictory. In an attempt to obtain clinically useful
information, the present discussion is limited to data from similar
studies concerning the diagnosis of the patient (CRC patients), the
type of treatment (OX/5-FU) and the genetic markers studied
(polymorphisms in genes related to the DNA-repair mechanisms).
Our results are subsequently discussed gene by gene.
ERCC1
An earlier pharmocogenomic study (Shirota et al, 2001) demons-
trated that intratumoral ERCC1 mRNA is an independent
predictive marker of survival for 5-FU and OX combination
chemotherapy. The authors showed a lower gene expression level
for the excision repair gene (ERCC1) in responders than in non-
responders. The same investigators (Park et al, 2003, Stoehlmacher
et al, 2004) devised retrospective studies to determine the
association between the ERCC1 codon 118 and 30-UTR poly-
morphism and the clinical outcome of platinum-based chemo-
therapy in 106 patients with refractory advanced CRC. They found
a significant association between the ERCC1 codon 118 SNP and
the clinical outcome: patients with the C/C genotype fared
significantly better in terms of OS than those with the thymine
allele. There was no significant association between the ERCC1
C8092A polymorphism and the outcome. In a similar study (with
ERCC1 codon 118 SNP), other authors (Viguier et al, 2005)
obtained contrasting results. The objective response rate to OX in
combination with 5-FU was significantly higher in the T/T
genotype group than in the C/T and C/C genotype groups (61.9,
42.3 and 21.4%, respectively; P¼ 0.018). In a comprehensive study
of common polymorphisms in genes of DNA repair (Moreno et al,
2006), it has been demonstrated that patients carrying a C/T and
a C/C genotype for the ERCC1 codon 118 polymorphism show
a worse prognosis, with a hazard ratio (HR) of 1.72 (95% CI:
1.04– 2.84; P¼ 0.036) compared with the T/T cases. The results
of a prospective study of 166 patients with advanced CRC treated
with first-line Folfox-4 chemotherapy were recently reported.
This study, which involved eight medical oncology units from
Italy (Ruzzo et al, 2007), demonstrated that the ERCC1-118 T/T
genotype is independently associated with adverse PFS in
univariate and multivariate analyses.
The three clinical parameters analysed (CR, PFS and OS) in this
work gave consistent results. Our findings demonstrate that
patients with the C/C genotype in the ERCC1 118 polymorphism
have a lower probability of response to treatment and a poorer
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Figure 1 Progression-free survival according to the genotype of (A) ERCC1-118 and (B) XPD 751.
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Figure 2 Overall survival according to the genotype of (A) ERCC1-118 and (B) XPD 751.
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outcome. The fact that these patients were selected, treated and
evaluated by the same clinical researcher, who was unaware of the
genotyping findings during the study, confirms the validity of the
criteria assessment of response and outcome, and lends further
support to our results.
The polymorphism at codon 118 changes a common codon
usage (AAC) to an infrequent codon (AAT), both coding for
asparagine. Interestingly, it has been proposed that this C4T
substitution impairs ERCC1 translation (Yu et al, 1997). In an
in vitro study, cells carrying the T allele showed a poor capacity to
repair the adducts induced by cisplatinum (Yu et al, 2000). These
data support the pharmacogenetic role of the 118 C4T change and
emphasise results that point to the T allele as a marker of a better
outcome in patients with CRC treated with OX/5-FU schemes.
XPD
In a study of 106 evaluable patients with advanced CRC who were
treated with an OX/5-FU regimen as a second-line treatment, the
impact of XPD 751 polymorphism was measured in PFS and
OS (Stoehlmacher et al, 2004). Using the XPD 751 Lys/Lys group
as a reference, the Gln/Gln group showed a 2.44-fold (95% CI:
1.09– 5.44) increased risk of dying, whereas patients with the
heterozygous genotype showed an intermediate RR of 1.87 (95%
CI: 1.06–3.31) (P¼ 0.049), a difference that supported a multi-
variant analysis (P¼ 0.037). The same polymorphism had no
impact on PFS. In an earlier study by the same team (Park et al,
2001), this polymorphism showed a similar effect on OS in 73
patients. Moreover, 24% of patients with the Lys/Lys genotype
responded in contrast to 10% with Lys/Gln and 10% with Gln/Gln
genotypes (P¼ 0.015). A further study (Ruzzo et al, 2007) of 166
patients with similar clinical characteristics indicates that this
polymorphism also influenced PFS. Lys/Gln and Gln/Gln patients
had HRs of 1.67 (P¼ 0.06) and 1.79 (P¼ 0.03), respectively,
compared with Lys/Lys patients, a difference that was maintained
in the multivariant analysis (HR 1.81, P¼ 0.04 and HR 2.21,
P¼ 0.01, respectively). Our results are in line with the above
findings. Sixty-seven per cent of our Lys/Lys patients responded
compared with 45% of Lys/Gln patients and 40.9% of Gln/Gln
patients (P¼ 0.047). Likewise, a better OS for Lys/Lys patients was
observed in the univariate and multivariate analyses. All the
available data, including our present results, indicate that the XPD
Lys751Gln polymorphism is a useful marker in predicting the
clinical outcome of platinum-containing chemotherapy. As the
present and previous reports are concordant with the results on
the XPD 751 variant, a promising role for this marker is proposed.
XRCC1
The first study on the utility of this gene as a pharmacogenetic
marker showed that it was predictive of clinical outcome in 61 CRC
patients treated with a combination of 130 mg m2 OX and
continuous infusion 5-FU (Stoehlmacher et al, 2001). In this
study, 73% of responders had an Arg/Arg genotype and three were
heterozygous, but 66% of non-responders showed a Gln/Gln or
Gln/Arg genotype (P¼ 0.038). Patients carrying at least one Gln
allele had a 5.2-fold increased risk to fail chemotherapy (95% CI:
1.21– 22.07). In a subsequent retrospective study that included 106
patients, the same team of investigators failed to confirm XRCC1
Arg399Gln as a prognosticator (Stoehlmacher et al, 2004). Similar
negative results were reported in a prospective study of 166
patients where no association was found between this marker and
PFS (Ruzzo et al, 2007). The results obtained in our study also did
not show any evidence of the existence of an association between
the three analysed SNPs (Arg194Trp, Arg280His and Arg399Gln)
and the clinical parameters that define the CR and survival.
The fact that the NER pathway seems to play a major role in the
repair of OX-induced DNA damage may account for the lack of
association between clinical outcomes of patients treated with OX-
containing regimens and polymorphisms in genes involved in
other DNA-repair pathways, as is the case of XRCC1, which
belongs to the BER system.
GSTP1
In an unpublished report, no association was found between GST
genotypes and OX-related cumulative neuropathy in a series of
patients with advanced CRC (McLeod et al, 2003). A recent study
(Lecomte et al, 2006) investigated the relationship between
GST polymorphisms and OX-related cumulative neuropathy. In a
group of 64 evaluable patients receiving a minimal cumulative
dose of 500 mg m2 of OX, the cumulative neuropathy grade 3 was
significantly more frequent in patients who were homozygous for
the GSTP1 105Ile allele than in patients homozygous or hetero-
zygous for the 105Val allele. The authors found no association
with the GSTM1, GSTT1 or GSTP1 exon 6 genotypes. The results of
this study suggested that the 105Val allele variant of the GSTP1
gene confers a significantly decreased risk of developing severe
OX-related cumulative neuropathy. We sought to ascertain the
existence of this relationship in our group of patients with a
comparable cumulative dose of OX. Our findings showed that
severe neurotoxicity was less frequent in our group of patients
than that reported by Lecomte et al (2006). This could be due to
the fact that all our patients received first-line treatment, whereas
20% of the patients in Lecomte’s series had received a prior
chemotherapy treatment. In our patients, as in those in Lecomte’s
study, severe neurotoxicity was more frequent in the Ile/Ile
homozygous patients than in the other groups. Nevertheless, this
result did not reach statistical significance, possibly because the
number of patients with severe neurotoxicity in our series was
small.
The results from this study of patients with advanced CRC
treated with first-line OX-based chemotherapy demonstrate the
following. (i) A functional polymorphism within the ERCC1 gene
(codon 118) can predict response and OS. (ii) Significant
associations exist between the XPD Lys751Gln polymorphism
and OS and response. As the present and previous reports are
concordant with the results on the XPD 751 variant, a promising
role for this marker is proposed. (iii) No significant association
can be found between GSTP1 Ile105Val and OX-induced neuro-
toxicity. In conclusion, our data support the hypothesis that there
is an inverse relationship between impaired DNA-repair capacity
mediated by the NER pathway and superior responses to OX
compounds.
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